Alnylam Pharmaceuticals (ALNY)

Executive Summary

Alnylam Pharmaceuticals is the preeminent pioneer in RNA interference (RNAi) therapeutics, with four FDA-approved products and a robust pipeline targeting rare and prevalent diseases. The company's platform enables gene silencing at the source, driving transformative outcomes in conditions like transthyretin-mediated amyloidosis (ATTR) and acute intermittent porphyria. With a market capitalization of ~$37.8B, Alnylam is transitioning from a biotech to a fully integrated biopharmaceutical company, underpinned by growing commercial revenues from ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. Key pipeline programs include vutrisiran for ATTR cardiomyopathy (sNDA under FDA review), zilebesiran for hypertension (Phase 2 completed), and ALN-BCAT for hepatocellular carcinoma (Phase 1 recruiting). The company's financial strength and execution track record support a positive outlook, though near-term catalysts are critical for sustained growth.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on vutrisiran (AMVUTTRA) for ATTR cardiomyopathy85% success
• Q4 2026Phase 2 data update for zilebesiran (ALN-AGT) in hypertension75% success
• Q1 2027Initial Phase 1 data for ALN-BCAT in advanced hepatocellular carcinoma60% success